Personalized medicine
The model also calculates biological ageing and survival patterns to support personalized health risk management.
The company says it is seeing an increased demand for testosterone hormone treatment.
Also, a startup from Melbourne has raised $1 million in pre-seed funding for its chemotherapy dosing AI.
The collaboration will combine AI and real-world data to accelerate oncology research and drug development.
Google will allow people to securely consolidate health data and control how it is shared.
Developed at the University of South Australia, it could help doctors safely deprescribe obsolete medications.
The round follows a $200 million seed raise earlier this year.
The funds will be used to expand operations in the U.S., Europe and Southeast Asia.
NUS Medicine’s latest model has outperformed DNA-based biological ageing clocks and demonstrated a stronger capability to predict mortality.
Trained on two million skin images, it can perform a range of clinical tasks unlike current models.